Swift Comments on Repercussions of U.S. Withdrawal from Iran Nuclear Pact
May 11, 2018
Washington Examiner
Partner Christopher Swift was quoted in a Washington Examiner article, “Business braces for fallout from Trump’s go-it-alone Iran strategy,” about expected changes in the global business climate in the wake of President Trump’s decision to scuttle the Iran nuclear deal.
Swift said the business environment is essentially returning to many of the conditions in effect before the 2015 signing of the Iran deal. “Suddenly these foreign subsidiaries of U.S. corporations become subject to primary sanctions again,” he said. “And everybody else in Europe is going to be subject to secondary sanctions again.”
Swift said the business environment is essentially returning to many of the conditions in effect before the 2015 signing of the Iran deal. “Suddenly these foreign subsidiaries of U.S. corporations become subject to primary sanctions again,” he said. “And everybody else in Europe is going to be subject to secondary sanctions again.”
People
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.